Wed, Sep 17, 2014, 10:09 AM EDT - U.S. Markets close in 5 hrs 51 mins


% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

  • biojax biojax Dec 5, 2013 1:35 PM Flag

    Reminder of potential


    Here's a list of some potential catalysts, other than the top two:

    ●End of enrollment for the ulcerative colitis trial

    ●Initiation of the GvHD phase II/III trial

    ●Initiation of the acute myocardial infarction phase II trial

    ●Realization of a partnership for the obesity drug

    ●Realization of a partnership for ischemic stroke

    ●Future grants or awards

    ●Potential milestone payments from RTI or Pfizer

    ●Legislation for Regenerative Medicine in Japan, may bring fast development path news.

    Now the real movers:

    The UC trial due at the end of the first quarter in 2014... easy pop to $7 on continuation to phase III * The phase III trial may be designed for crohn's disease.

    The IS trial due mid 2014... easy pop to $10 and that's being conservative with new laws in Japan. Phase III may not even be needed to market it in Japan.

    A holder of this stock asked that Athersys have an offering... Athersys did without a severe undercut of the share price. Couple this with the ability to draw down on the Aspire deal if needed and we have a bright future for Athersys ahead. Stroke is a slam dunk - follow the trials and Youtube video. The guy was healing faster than normal. .

    Sentiment: Strong Buy

    This topic is deleted.
1.34+0.01(+0.75%)10:05 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.